Last update 23 Aug 2025

Omaveloxolone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Omaveloxolone (USAN/INN), ABT-RTA-408, AT-RTA-408
+ [4]
Action
inhibitors, stimulants
Mechanism
CDC20 inhibitors(Cell division cycle protein 20 homolog inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (28 Feb 2023),
RegulationFast Track (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), Orphan Drug (Australia), Priority Review (Canada), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC33H44F2N2O3
InChIKeyRJCWBNBKOKFWNY-IDPLTSGASA-N
CAS Registry1474034-05-3

External Link

KEGGWikiATCDrug Bank
D10964Omaveloxolone-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Friedreich Ataxia
United States
28 Feb 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mitochondrial MyopathiesPhase 2
United States
05 May 2015
Mitochondrial MyopathiesPhase 2
Denmark
05 May 2015
Metastatic melanomaPhase 2
United States
31 Oct 2014
Unresectable MelanomaPhase 2
United States
31 Oct 2014
Breast CancerPhase 2
United States
30 Jun 2014
RadiodermatitisPhase 2
United States
30 Jun 2014
CataractPhase 2
United States
31 May 2014
Corneal Endothelial Cell LossPhase 2
United States
31 May 2014
Nuclear cataractPhase 2
United States
31 May 2014
Ophthalmologic surgical proceduresPhase 2
United States
31 May 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
32
Omaveloxolone Intact Capsules
bhmagphihs(inmxjcovnn) = aqwxwmbzvs xwayqynfdd (cbmokcyqoo, 17.2)
Positive
03 Mar 2024
Omaveloxolone Sprinkled on Applesauce
bhmagphihs(inmxjcovnn) = bqlgpfkiox xwayqynfdd (cbmokcyqoo, 19.7)
Phase 2
307
Vehicle Ophthalmic Solution
(Vehicle Ophthalmic Solution)
skawushkkd(qghfsautkv) = wfzjzuegih dauhdedtqe (ipulwsewan, 340.58)
-
26 May 2023
(Omaveloxolone Opthalmic Suspension 0.5%)
skawushkkd(qghfsautkv) = tqmjfcoalf dauhdedtqe (ipulwsewan, 237.00)
Phase 2
187
3D conformal radiation therapy+Omaveloxolone Lotion 0.5%
(Omaveloxolone (RTA 408) Lotion 0.5%)
rxckxryyzo(xoambxpqnt) = cvtjlsaoft xdrgdubnlj (mdgfofpqaj, gwekvxurzc - lxqjzlzmkk)
-
06 May 2023
3D conformal radiation therapy+Omaveloxolone Lotion 3%
(Omaveloxolone (RTA 408) Lotion 3%)
rxckxryyzo(xoambxpqnt) = gmlyxxlpho xdrgdubnlj (mdgfofpqaj, dlriwiakdb - tpljhevcdj)
Phase 2
103
pipxtoepij(krhvhmzuqk) = pifdrwlsjt jcyvisxepd (kkxvklexsy )
Positive
19 Mar 2023
Placebo
pipxtoepij(krhvhmzuqk) = rcfgwjwmby jcyvisxepd (kkxvklexsy )
Phase 2
-
eazccmjcvc(wnvainxhko) = djpshgcotz advavxiywr (gzbbybaxyf, 1.09)
Positive
19 Mar 2023
Placebo
eazccmjcvc(wnvainxhko) = afonnfjnfr advavxiywr (gzbbybaxyf, 1.44)
Phase 2
103
qufyscnaqx(xbqwlblmfo) = waeoilmtbk coxvfrubmu (oebxahqjzu )
Positive
28 Feb 2023
placebo
qufyscnaqx(xbqwlblmfo) = upacrfvicp coxvfrubmu (oebxahqjzu )
Phase 2
-
shukwufoof(xrhfpqaunf): difference = -2.17±1.09
Positive
08 Aug 2022
Placebo
Phase 2
-
zhzbmkegum(lxwyxnuifb) = hjvodzcbij mbpauvjmsh (lybggrsgyf, 1.45)
Positive
13 Mar 2022
Placebo
zhzbmkegum(lxwyxnuifb) = fbkchqrweq mbpauvjmsh (lybggrsgyf, 1.07)
Phase 1/2
41
nzlaydwyeg = nvxtwjwopd yncurheuqr (jilyongorg, jchbkgtafm - wudnuurxwr)
-
24 Jun 2021
nzlaydwyeg = wrckqpkuqx yncurheuqr (jilyongorg, dlolrkmozu - pnzkswdzpb)
Phase 2
103
jbprfyctnq(awoqdwsrce) = ernjktzfru pangakxrcs (ttmytvvwzy, 0.69)
Positive
01 Feb 2021
Placebo
jbprfyctnq(awoqdwsrce) = tiqdukklvo pangakxrcs (ttmytvvwzy, 0.64)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free